Program
SR604
A development code.
Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai RAAS Blood Products | 44 open or running | phase 3since Oct 9, 2026 | May 26, 2026 | Dec 31, 2026phase 2 · NCT07644832 |
| Equilibra Bioscience | 11 open or running | phase 1since Mar 20, 2024 | Mar 20, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 20, 2024First study: phase 1 study in Hemophilia ANew to Equilibra BioscienceEquilibra Bioscience · NCT06349473 · 31 planned · United States, Canada
- May 26, 2026Shanghai RAAS Blood Products's first study: phase 2 study in Hemophilia ANew to Shanghai RAAS Blood ProductsShanghai RAAS Blood Products · NCT07644832 · 76 planned · China
- Jun 1, 2026Phase 2 study in von Willebrand DiseasesShanghai RAAS Blood Products · NCT07640893 · 24 planned · China
- Jul 14, 2026Phase 2 study in Factor VII DeficiencyShanghai RAAS Blood Products · NCT07711158 · 12 planned · China
- Oct 9, 2026Phase 3 study in Hemophilia APhase 3 reachedShanghai RAAS Blood Products · NCT07876674 · 90 planned
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Hemophilia AShanghai RAAS Blood Products · NCT07644832
- Feb 2027Primary completion: phase 2 study in Factor VII DeficiencyShanghai RAAS Blood Products · NCT07711158
- Sep 30, 2027Primary completion: phase 3 study in Hemophilia AShanghai RAAS Blood Products · NCT07876674
- Dec 31, 2027Primary completion: phase 2 study in von Willebrand DiseasesShanghai RAAS Blood Products · NCT07640893
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07876674Hemophilia A | 3 | Not yet recruiting | Shanghai RAAS Blood Products | Sep 30, 2027 | 90 |
| NCT07711158Factor VII Deficiency · China | 2 | Not yet recruiting | Shanghai RAAS Blood Products | Feb 2027 | 12 |
| NCT07640893von Willebrand Diseases · China | 2 | Recruiting | Shanghai RAAS Blood Products | Dec 31, 2027 | 24 |
| NCT07644832Hemophilia A · China | 2 | Recruiting | Shanghai RAAS Blood Products | Dec 31, 2026 | 76 |
| NCT06349473Hemophilia A · United States, Canada | 1 | Recruiting | Equilibra Bioscience | Sep 28, 2026 | 31 |
How it is read
Names in the registry
- “SR604”, 7 entries
Codes read as this program: SR604.
Conditions, from the studies’ own filings
- Hemophilia A, 3 studies
- von Willebrand Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.